Can Medical Cannabis Alleviate Dementia Symptoms? 

Interest in medical cannabis has surged in recent years, leading many families to ask whether it might help people living with dementia. According to the NHS and NICE, cannabis-based medicinal products are sometimes prescribed for severe epilepsy, chemotherapy-related nausea, or multiple sclerosis, but not for dementia. 

While dementia can cause distressing symptoms such as agitation, sleep disturbance, and anxiety, current evidence shows no consistent or reliable benefit from cannabis-based medicines in treating these problems. Most studies to date have been small and experimental, and any short-term improvements appear to be mild and often similar to placebo results (NICE NG144). 

What The Research Shows 

Recent reviews and clinical trials between 2022 and 2025 have tested compounds such as THC, CBD, and nabiximols (Sativex) for behavioural symptoms in Alzheimer’s and related dementias. According to analyses published in the BMJ (2023) and PubMed (2024), these studies have not shown meaningful changes in cognition, memory, or disease progression. 

Some small pilot trials have noted temporary improvements in agitation and caregiver’s distress, but the effects were modest and inconsistent. Importantly, side effects such as sedation, confusion, dizziness, and worsening disorientation have also been observed, which can pose significant risks for older adults with dementia. 

The UK Position on Prescribing 

Under current UK law, medical cannabis can only be prescribed by specialist doctors under very restricted circumstances. NICE guidance (NG144) specifically advises that there is insufficient evidence to support its use in dementia, and that prescriptions should occur only within the context of clinical trials or exceptional, off-label cases. 

The Royal College of Psychiatrists and Alzheimer’s Society UK both echo this stance, cautioning that cannabis products should not be used outside clinical research until larger, high-quality trials demonstrate clear benefit and safety. Families are therefore urged to approach over-the-counter CBD or online cannabis products with care, as these are not regulated medical treatments and can interact with prescribed medications. 

Potential Risks and Safety Considerations 

Because dementia often affects older adults with multiple health conditions, the risks of cannabis-based treatments can outweigh potential benefits. Reported adverse effects include: 

• Sedation and daytime drowsiness 

• Worsening confusion or hallucinations 

• Dizziness, increasing the risk of falls 

• Possible interactions with antipsychotic or sedative drugs 

According to NICE and NHS guidance, the lack of long-term safety data means that even mild side effects could become significant for people with cognitive impairment. 

Where Research Is Heading 

Scientists are continuing to study how cannabinoids interact with the brain’s endocannabinoid system, which plays a role in inflammation and neuroprotection. Alzheimer’s Research UK is currently funding exploratory projects to understand whether specific cannabinoid compounds might one day reduce neuroinflammation or slow disease progression. 

However, experts agree that at present, no cannabinoid-based medicine has proven benefits for dementia symptoms or progression, and any future approval will depend on rigorous, large-scale clinical evidence. 

Clinical Bottom Line 

• No strong evidence supports medical cannabis for dementia-related symptoms. 

• NICE and NHS do not recommend its routine use for dementia. 

• Small studies show minimal benefits, mainly short-term reductions in agitation. 

• Side effects, including confusion and falls, remain a significant concern in older adults. 

• Use should only occur within clinical trials or under specialist supervision. 

About AlleviMed  

If you’re exploring whether medical cannabis could be appropriate for a loved one, the best next step is to speak with a specialist clinician experienced in both neurology and cannabinoid medicine. Services like AlleviMed (launching soon) can provide eligibility consultations to help patients understand whether cannabis-based treatment might be legally and clinically suitable for their condition. 

Takeaway 

At present, medical cannabis is not recommended for dementia. According to NICE, NHS, and Alzheimer’s Society UK, there is not enough evidence that it meaningfully improves cognition, behaviour, or quality of life, and potential harms remain a concern. Ongoing research may change that picture in future, but for now, supportive care and expert medical advice remain the safest path forward.